NeuroPace, Inc. has announced preliminary results from the one-year data in the Nautilus study, evaluating the safety and ...

NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA ...

Shares of NeuroPace Inc (NASDAQ:NPCE) plummeted 36.1% today after the company reported that its primary effectiveness endpoint for the NAUTILUS study did not reach statistical significance in the ...

Shares of NeuroPace sank after the company said the study of its RNS system for treating drug-resistant idiopathic generalized epilepsy missed a primary endpoint. The stock was down 37% at $11.15 in ...

NeuroPace (NASDAQ:NPCE) stock drops as the company's NAUTILUS study for RNS System misses the primary endpoint for the ...

NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study ...

NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met ...

NeuroPace Inc. (NASDAQ:NPCE) saw its stock nosedive by 36.1% today after announcing that its NAUTILUS clinical trial failed ...

After a medically uneventful pregnancy Edie was born at 38 weeks and weighing 5lb 4oz. Mum Cheryl said the tot, who was 'all ...

"I could not believe she would not wake up - we still tried to look for a positive. You do not believe the worst will happen ...

"I left the room and was watching her on the baby monitor. She was using her dummy as a stick to rattle against the crib ...

Sevierville, and Sen. Tom Hatcher, R-Maryville, have secured $500,000 for the Epilepsy Foundation of East Tennessee.